



Genomic Health, Inc.  
Investor Relations Department  
301 Penobscot Dr.  
Redwood City, CA 94063  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: GHDX

Last Trade:	32.45
Trade Time:	4:00 PM ET Feb 20, 2018
Change:	-0.46  (-1.398%)
Day Range	32.25 - 33.39
52-Week Range	26.54 - 37.50
Volume	250,835

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

**Genomic Health, Inc.** (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Feb 5, 2018*  
[Oncotype DX® Genomic Prostate Score™ Test Increases Use of Active Surveillance by 30 Percent in Low-risk Patients, Resulting in Greater Adherence to Guideline-based Care](#)

*Dec 21, 2017*  
[Genomic Health to Present at the 36th Annual J.P. Morgan Healthcare Conference](#)

*Dec 11, 2017*  
[Genomic Health Presents New Data Demonstrating Value of Oncotype DX® to Optimize Breast Cancer Outcomes and Reduce Treatment Burden throughout Disease Continuum](#)

*Dec 6, 2017*  
[Genomic Health Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Oncotype DX® Genomic Prostate Score™ Test for Potential Drug Development](#)

*Nov 30, 2017*  
[Genomic Health Announces Presentation of 10 Oncotype DX® Studies at the 2017 San Antonio Breast Cancer Symposium Demonstrating Test's Unique Value in Predicting Neoadjuvant Treatment Benefit and Guiding Breast Cancer Staging](#)

## Financials & Filings [\[ View all \]](#)

*Mar 15, 2017*  
[Annual Report \(10-K\)](#)

*Apr 28, 2017*  
[Proxy Statement \(DEF 14A\)](#)

*Nov 9, 2017*  
[Quarterly Report \(10-Q\)](#)

*Aug 4, 2017*  
[Quarterly Report \(10-Q\)](#)

*May 10, 2017*  
[Quarterly Report \(10-Q\)](#)

